The Medicare part D plan could negatively influence ESRX due to regulatory risk and losses in its consumer base as the plan D market becomes increasingly competitive.
The merger between CVS and Caremark could significantly increase competition in the PBM sector, especially in the long run once CVS/Caremark has solved all of its integration problems.